US · STE · MEDICAL - SPECIALTIES
STERIS plc (STE) intrinsic value and stock valuation
$255.76as of 2026-11-21 · Mkt cap 22.68B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
STERIS plc DCF and intrinsic value
InvestorsCraft values STE with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from STE’s statements →
STERIS plc Graham Number
Graham Number: $114.82d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2012–2026, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- DexCom, Inc. (DXCM) $79.32
- Biogen Inc. (BIIB) $249.59
- Waters Corporation (WAT) $440.45
- Quest Diagnostics Incorporated (DGX) $258.28
- Koninklijke Philips N.V. (PHG) $28.61
- Labcorp Holdings Inc. (LH) $367.13
- West Pharmaceutical Services, Inc. (WST) $390.30
- Zimmer Biomet Holdings, Inc. (ZBH) $101.10
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $5.94B | $5.46B | $5.14B | $4.54B | $4.22B |
| Operating income | $1.1B | $866.6M | $836.1M | $791.1M | $477.8M |
| Net income | $785.1M | $614.6M | $378.2M | $107M | $243.9M |
| EPSd | $7.95M | $6.2M | $3.81M | $1.07M | $2.48M |
| Operating cash flow | $1.34B | $1.15B | $973.3M | $757M | $684.8M |
| Capital expenditure | -$-369M | -$-370.09M | -$-360.33M | -$-361.97M | -$-287.56M |
| Free cash flow | $972.4M | $778M | $613M | $395M | $397.3M |
| Total assets | $10.7B | $10.1B | $11.1B | $10.8B | $11.4B |
| Total debt | $2.09B | $2.2B | $3.38B | $3.25B | $3.28B |
| Net debt | $1.65B | $2.03B | $3.18B | $3.04B | $2.93B |
| Total equity | $7.2B | $6.62B | $6.32B | $6.09B | $6.54B |
| Cash and short-term investments | $439.6M | $171.7M | $207M | $208.4M | $348.3M |
Income statement
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $5.94B | $5.46B | $5.14B | $4.54B | $4.22B |
| Cost of revenue | $3.31B | $3.06B | $2.92B | $2.56B | $2.34B |
| Gross profit | $2.63B | $2.4B | $2.22B | $1.98B | $1.88B |
| Research and development expenses | $112.9M | $107.7M | $103.7M | $98.5M | $86.7M |
| Selling, general and administrative expenses | $1.41B | $1.33B | $1.25B | $1.09B | $1.32B |
| Other expenses | $4.1M | $94.2M | $26.1M | $480K | $50K |
| Operating expenses | $1.52B | $1.54B | $1.38B | $1.19B | $1.41B |
| Cost and expenses | $4.83B | $4.59B | $4.3B | $3.75B | $3.75B |
| Interest income | $9.8M | $8.4M | $11M | $0.00 | $6.28M |
| Interest expense | $60.7M | $86.3M | $144.4M | $110.8M | $89.5M |
| Depreciation and amortization | $486.5M | $476.2M | $565.2M | $422.5M | $553.1M |
| Ebitda | $1.59B | $1.36B | $1.41B | $1.23B | $1.01B |
| Operating income | $1.1B | $866.6M | $836.1M | $791.1M | $477.8M |
| Total other income/expenses, net | -$-54.5M | -$-70.43M | -$-133.31M | -$-110.83M | -$-111.01M |
| Income before tax | $1.05B | $796.2M | $702.8M | $680.3M | $366.8M |
| Income tax expense | $262.2M | $184.7M | $149.5M | $124.1M | $82.3M |
| Net income | $785.1M | $614.6M | $378.2M | $107M | $243.9M |
| Weighted average shares outstanding | $98.2M | $98.6M | $98.8M | $99.7M | $97.5M |
| Weighted average diluted shares outstanding | $98.7M | $99.1M | $99.4M | $100.3M | $98.3M |
Balance sheet
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $439.6M | $171.7M | $207M | $208.4M | $348.3M |
| Net receivables | $1.09B | $1.04B | $1.01B | $865M | $799M |
| Inventory | $631.8M | $581.3M | $674.5M | $604.4M | $575M |
| Total current assets | $2.39B | $2B | $2.87B | $2.01B | $1.88B |
| Property, plant and equipment, net | $2.32B | $2.11B | $1.94B | $1.8B | $1.74B |
| Goodwill and intangible assets | $5.81B | $5.95B | $6.19B | $5.96B | $7.73B |
| Long-term investments | $0.00 | $14.3M | $0.00 | $0.00 | $8.13M |
| Total non-current assets | $8.34B | $8.15B | $8.19B | $8.81B | $9.54B |
| Total assets | $10.7B | $10.1B | $11.1B | $10.8B | $11.4B |
| Accounts payable | $338.8M | $280.8M | $251.7M | $264.2M | $225.7M |
| Short-term debt | $154.7M | $159.2M | $117.2M | $90.1M | $179.4M |
| Deferred revenue | $59.1M | $57.5M | $70.5M | $85.7M | $110.8M |
| Total current liabilities | $1.15B | $1.02B | $931.1M | $861.8M | $922.2M |
| Long-term debt | $1.93B | $2.04B | $3.27B | $3.16B | $3.1B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $2.39B | $2.51B | $3.82B | $3.87B | $3.96B |
| Capital lease obligations | $119.6M | $158.8M | $177.1M | $169.6M | $191.5M |
| Total liabilities | $3.54B | $3.53B | $4.75B | $4.73B | $4.88B |
| Common stock | $0.00 | $4.42B | $4.54B | $4.49B | $4.74B |
| Retained earnings | $3.02B | $2.48B | $2.09B | $1.91B | $2B |
| Accumulated other comprehensive income (loss) | -$-113.1M | -$-292.34M | -$-328.66M | -$-320.71M | -$-209.81M |
| Total equity | $7.2B | $6.62B | $6.32B | $6.09B | $6.54B |
| Total investments | $0.00 | $14.3M | $0.00 | $0.00 | $8.13M |
| Total debt | $2.09B | $2.2B | $3.38B | $3.25B | $3.28B |
| Net debt | $1.65B | $2.03B | $3.18B | $3.04B | $2.93B |
Cash flow statement
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Net income | $785.1M | $616.1M | $380.1M | $105.8M | $242.9M |
| Depreciation and amortization | $486.5M | $476.2M | $565.2M | $552.9M | $553.1M |
| Stock-based compensation | $61.7M | $57.4M | $56.5M | $39M | $57.7M |
| Change in working capital | $27.2M | $66.5M | -$-146.08M | -$-250.02M | -$-149.28M |
| Accounts receivable | -$-25.1M | -$-28.82M | -$-128.07M | -$-133.3M | -$-51.97M |
| Inventory | -$-24M | $73.1M | -$-37.45M | -$-123.92M | -$-102.92M |
| Accounts payable | $51.1M | $33.6M | -$-18.96M | $53.3M | $14.9M |
| Net cash provided by operating activities | $1.34B | $1.15B | $973.3M | $757M | $684.8M |
| Investments in property, plant and equipment | -$-369M | -$-370.09M | -$-360.33M | -$-361.97M | -$-287.56M |
| Acquisitions, net | -$-20.1M | $760.4M | -$-536.8M | -$-35.95M | -$-380.74M |
| Net cash used for investing activities | -$-512.5M | $388.8M | -$-887.36M | -$-383.33M | -$-666.56M |
| Common stock issued | $32.9M | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-235.5M | -$-211.32M | -$-11.77M | -$-308.56M | -$-55.78M |
| Dividends paid | -$-241.8M | -$-219.88M | -$-200.57M | -$-183.5M | -$-163.17M |
| Net cash used for financing activities | -$-568.2M | -$-1.57B | -$-85.19M | -$-498.72M | $115.8M |
| Net change in cash | $267.9M | -$-35.32M | -$-1.34M | -$-139.96M | $127.8M |
| Cash at end of period | $439.6M | $171.7M | $207M | $208.4M | $348.3M |
| Operating cash flow | $1.34B | $1.15B | $973.3M | $757M | $684.8M |
| Capital expenditure | -$-369M | -$-370.09M | -$-360.33M | -$-361.97M | -$-287.56M |
| Free cash flow | $972.4M | $778M | $613M | $395M | $397.3M |
Line items
Line items
Line items
About STERIS plc
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting. In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment. It serves healthcare providers, medical device and pharmaceutical manufacturers, biopharmaceutical manufacturing facilities, and hospitals. The company was formerly known as New STERIS Limited and changed its name to STERIS plc in November 2015. STERIS plc was founded in 1985 and is headquartered in Mentor, Ohio.
- CEO
- Daniel A. Carestio
- Employees
- 17.94K
- Beta
- 0.92
Included in
Explore
Frequently asked questions
What is the intrinsic value of STERIS plc (STE)?
STERIS plc (STE) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is STE undervalued?
STE trades at a price of $255.76 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.